Farmaceutici Procemsa S.P.A.
Italian CDMO founded in 1939, developing and manufacturing food supplements, probiotics, medical devices, and cosmetics on a contract basis for multinational, national, and e-commerce brands across 63 countries from three Italian plants, now expanding into a pan-European group via acquisitions.
- Company typePrivate
- Founded1939
- HeadquartersNichelino, Italy
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Farmaceutici Procemsa S.P.A. does
Farmaceutici Procemsa S.P.A. is an Italian Contract Development and Manufacturing Organization (CDMO) headquartered in Nichelino (Turin), founded in 1939, that develops and produces food supplements, probiotics, medical devices, and cosmetics exclusively on a third-party/private-label basis. The company operates from three Italian manufacturing sites — Via Vernea (7,740 sqm, headquarters, R&D, logistics, production), Via Mentana (3,040 sqm, registered office, production, transition warehouse, R&D lab), and a Central Logistic Centre inaugurated in May 2020 with 5,500 pallet spaces — together providing 9,370 pallet spaces across 2,100 sqm of warehousing and a dedicated ISO class 8 probiotic facility. Production covers tablets (single/double/triple layer, chewable, coated, effervescent, gastro-resistant, probiotic-based), hard gelatin and HPMC capsules, single-dose sachets/sticks/strips, powders and granulates, liquids (solutions, syrups, dispersions, suspensions, oils), and semisolid forms (emulsions, ointments, gels, medical devices in PE and aluminum tubes). Underlying the CDMO platform are eight proprietary technology families (LIMOR, IOR, MOR, multi-layer tablet, increased oral release, gastro-resistant, Tabgum, probiotic stability) plus proprietary raw materials ALFAMEL and ROSHIELD protected by three international patents each, and granted patents spanning Italy, EU, and US on propolis formulations, food emulsions, and anti-cellulite topical compositions.
The business model is pure B2B contract manufacturing and development: Procemsa charges manufacturing fees, formulation development, and dossier/regulatory support to multinational corporations, national brands, and e-commerce brands across Health & Wellbeing, Pharma, and Makeup & Skincare, exporting to 63 countries. The company does not sell under its own consumer brand. Customers benefit from an integrated service spanning idea generation, R&D, regulatory and scientific dossier development, ICH stability studies, production, packaging, and logistics. The firm holds a dense regulatory stack — GMP/FDA (registration 15721871314), ISO 9001, ISO 13485, ISO 14001, ISO 45001, IFS Food v6, NSF/ANSI 455-2, HALAL and BIOLOGIC on-demand — with manufacturing plants recognized by health authorities of Canada, UAE, Kuwait, Oman, Qatar, Iraq, Iran, Israel, Algeria, Benin, Jordan, Sudan, Lebanon, Yemen, and Bahrain.
Since Investindustrial acquired 70% in June 2019 (Sertorio family retaining 30%), Procemsa has executed an aggressive European CDMO roll-up: OFI Officina Farmaceutica Italiana (Dec 2020, Italy), Aakamp (Mar 2022, Germany), and a signed agreement for majority control of Master Pharm S.A. (Aug 2023, Poland). Post-Master Pharm, the group is projected to exceed €150M revenue across 8 plants and 700+ employees. Leadership transitioned on 21 July 2023, with Alessandro Sertorio moving to Non-Executive Chairman and Sagi Cohen — formerly Chairman of the Procemsa Board with senior board experience at 7-Eleven, Tnuva, Caesarstone, and Aran Packaging — installed as Group CEO. Filippo Sertorio continues as President of the Group and Chief Sustainability Officer; the group committed in 2022 to a Science Based Targets 23% absolute scope 1+2 GHG reduction by 2030 and received a Sustainability Award from Kon Group, Credit Suisse, and Forbes.
Farmaceutici Procemsa S.P.A. firmographics
Firmographics- Name
- Farmaceutici Procemsa S.P.A.
- Legal name
- Farmaceutici Procemsa S.p.A.
- Website
- https://procemsa.it
- Company type
- Private
- Founded year
- 1939
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Italian CDMO founded in 1939, developing and manufacturing food supplements, probiotics, medical devices, and cosmetics on a contract basis for multinational, national, and e-commerce brands across 63 countries from three Italian plants, now expanding into a pan-European group via acquisitions.
- Ownership category
- akta.pro rank
Farmaceutici Procemsa S.P.A. industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Food Manufacturing (311)
- SIC
- Food And Kindred Products (2000), Pharmaceutical Preparations (2834), Miscellaneous Food Preparations & Kindred Products (2090)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ), Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI), Fortification Ingredients (Vitamins, Minerals, Nutrient Premixes) (CRADAOAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where Farmaceutici Procemsa S.P.A. is headquartered
LocationHeadquarters
- HQ city
- Nichelino
- HQ country
- Italy
- HQ region
- Europe
Offices3 records
Markets served
Farmaceutici Procemsa S.P.A. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Procemsa operates exclusively as a CDMO (Contract Development and Manufacturing Organization), developing and producing Food Supplements, Medical Devices, Cosmetics, and Functional Foods for third parties. Revenue is generated through manufacturing fees, formulation development services, and product development across all solid and liquid pharmaceutical forms. The company offers comprehensive services from idea generation to logistics.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Farmaceutici Procemsa S.P.A. product offering
Product offeringCore offering
Farmaceutici Procemsa S.p.A. operates as a B2B Contract Development and Manufacturing Organization (CDMO), developing and producing food supplements, probiotics, medical devices, cosmetics, and functional foods exclusively for third-party brands. The company provides comprehensive services spanning product formulation, R&D, production in multiple pharmaceutical forms (tablets, capsules, sachets, powders, liquids, and semi-solids), packaging, regulatory support, and logistics.
Product overview
Farmaceutici Procemsa S.P.A. is a Contract Development and Manufacturing Organization (CDMO) offering a comprehensive portfolio of health and wellness products for third parties. The core portfolio consists of Food Supplements, Probiotics, Medical Devices (Class I, II, III), and Cosmetics, supported by proprietary ingredients ALFAMEL and ROSHIELD. Production capabilities span multiple pharmaceutical forms including Tablets, Capsules, Sachets/Sticks/Strips, Powders/Granulates, Liquids, and Semisolid Forms. The company operates three manufacturing plants with dedicated areas for different product categories, including an independent probiotic production facility. Services include Private Label manufacturing and Functional Food development. The integrated quality system covers all stages from R&D through production and packaging, supported by specialized laboratories and equipment.
Differentiator
Problem solved
Functional benefit
Products and services
- Food Supplements
Quantifiable outcome
- Presence in 63 countries worldwide
- +3 more outcomes
Companies that use Farmaceutici Procemsa S.P.A.
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Farmaceutici Procemsa S.P.A. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature11 records
Farmaceutici Procemsa S.P.A. partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, minor and historical.
- Master Pharm S.A.coreProcemsa signed agreement to acquire majority stake in Master Pharm, a leading CDMO in Poland founded in 2002 and headquartered in Łódź. Master Pharm manufactures dietary supplements in tablets, soft gels, capsules, sachets and drops. The acquisition reinforces Procemsa's European presence and will bring group revenue to over €150 million with 8 plants and 700+ employees. Expected to close later in 2023.
- AakampcoreProcemsa acquired Aakamp in Germany in March 2022, expanding the group's manufacturing footprint to Germany as part of the consolidation strategy of the European CDMO market.
- OFI Officina Farmaceutica Italiana SpAcoreProcemsa acquired OFI in December 2020, establishing a leading group in contract manufacturing for food supplements, cosmetics, and medical devices. OFI became part of the Procemsa Group portfolio.
- OurvitaminorOurvita is identified as the parent group of Procemsa, with Procemsa listed as 'Company part of Ourvita' on the Procemsa website.
- Doppel SpAhistoricalHistorical affiliation with Doppel SpA from 2003 (Sertorio 60% - Doppel 40%), with ownership structure changing to Sertorio 75.3% - Doppel 24.7% in 2016. Procemsa returned to 100% Sertorio family ownership in 2018 before Investindustrial investment.
- Research InstitutionsminorProcemsa collaborates with research institutions for exclusive raw materials development, including university studies for proprietary ingredients like ALFAMEL and ROSHIELD extracts.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Farmaceutici Procemsa S.P.A. competitors and assessment
Company assessmentDirect peers
- Aenova: Aenova is one of Europe's largest pharmaceutical and nutraceutical CDMOs, offering solid and semi-solid dosage form development and manufacturing across multiple sites in Germany, Italy, and Switzerland — directly comparable to Procemsa's pan-European CDMO model.
- Recipharm: Recipharm is a leading European CDMO (acquired by EQT in 2021) offering contract development and manufacturing of pharmaceuticals and consumer health products across multiple European sites, directly comparable in scale, regulatory scope, and customer mix to Procemsa.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Farmaceutici Procemsa S.P.A. social profiles
Digital presenceFarmaceutici Procemsa S.P.A. compliance and trust
Trust signalCompliance9 records
Farmaceutici Procemsa S.P.A. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Farmaceutici Procemsa S.P.A. leadership team
Management profileNumber of profiles
Profiles3 records
Farmaceutici Procemsa S.P.A. subsidiaries and ownership
Company hierarchySubsidiaries3 records
Farmaceutici Procemsa S.P.A. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Farmaceutici Procemsa S.P.A. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Farmaceutici Procemsa S.P.A.
What does Farmaceutici Procemsa S.P.A. do?
Farmaceutici Procemsa S.p.A. operates as a B2B Contract Development and Manufacturing Organization (CDMO), developing and producing food supplements, probiotics, medical devices, cosmetics, and functional foods exclusively for third-party brands. The company provides comprehensive services spanning product formulation, R&D, production in multiple pharmaceutical forms (tablets, capsules, sachets, powders, liquids, and semi-solids), packaging, regulatory support, and logistics.
Is Farmaceutici Procemsa S.P.A. a public or private company?
Farmaceutici Procemsa S.P.A. is a private company. It is classified as private equity controlled and is currently operating.
When was Farmaceutici Procemsa S.P.A. founded?
Farmaceutici Procemsa S.P.A. was founded in 1939. It employs 101 to 250 people.
Where is Farmaceutici Procemsa S.P.A. based?
Farmaceutici Procemsa S.P.A. is headquartered in Nichelino, Italy, in the Europe region.
How does Farmaceutici Procemsa S.P.A. make money?
One revenue line is on record: contract Manufacturing Services.
Who are Farmaceutici Procemsa S.P.A.'s main competitors?
Direct peers on record are Aenova and Recipharm.
Does Farmaceutici Procemsa S.P.A. have an API?
No public API is recorded for Farmaceutici Procemsa S.P.A..
What industry is Farmaceutici Procemsa S.P.A. in?
Farmaceutici Procemsa S.P.A.'s product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGAKAJ, Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA). Its NAICS code is 325412 and its SIC code is 2000.